Navigation Links
Agent in Medical Technology
... to evaluate KRX-0401 (perifosine) as a single agent treatment for recurrent solid tumors in pediatric ...
KRX-0401 is a novel, oral, anticancer agent that modulates Akt and several other important ... Cancer Institute demonstrated that single agent perifosine not only induced tumor regression and ...
... obtained the rights to develop and market a novel agent for the prevention and treatment of neuropathies ... CXB909, is a small molecule, orally active agent that enhances the effects of nerve growth factor ... "In preclinical studies, our small molecule agent CXB909 has been shown to increase the action of ...
... Regardless of the particular anti-TNF-alpha agent previously used in treatment (adalimumab, ... the efficacy and safety of an anti-TNF-alpha agent in patients previously treated with other ... Reasons for discontinuation of prior anti-TNF agent included lack of efficacy (58 percent), ...
... KRX-0401 Demonstrates Impressive Single agent Efficacy in Patients who Progressed after Failing ... as a secondary endpoint. Best response to single agent perifosine was as follows: Group ... group, best response and median PFS to single agent perifosine was as follows: Group ...
... less toxic and more active than the FDA approved agent ribavirin. Preliminary in vivo toxicology ... "We believe that the addition of a novel agent such as PG301029 to the current standard of care ... based on their transcription targeted therapeutic agent platform. For further information ...
... our belief that ProLindac is an active platinum agent with a favorable side effect profile," stated ... kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to ... ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. Access ...
... benefit for pixantrone when used as single agent therapy in the treatment of multiple relapsed ... prior therapy with doxorubicin, an agent in a similar class with cumulative ... (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular ...
... the program. The Altropane molecular imaging agent is being developed by Alseres to aid in the early ... "We believe that Altropane represents an imaging agent that is not only 'first-in-class' in the U.S. ... Altropane Altropane is a molecular imaging agent that specifically binds to the dopamine ...
... mechanism. Angiolix(R) is a promising novel agent for anti-angiogenic cancer therapy. Angiolix has ... kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to ... ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For ...
... and efficacy of Macroplastique to another bulking agent used in the control group. In the Macroplastique ... available bioabsorbable urethral bulking agent for one year. Of the 247 study ... Macroplastique(R) Implants, an injectable bulking agent for the treatment of adult female stress urinary ...
... Injection, an intravenous sedative-hypnotic agent for monitored anesthesia care (MAC) sedation in ... for use as an intravenous sedative-hypnotic agent for sedation in adult patients undergoing ... LUSEDRA is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) ...
... demonstrated that perifosine is an active, novel agent with the potential to provide clinical benefit to ... Macroglobulinemia (WM) Single agent perifosine achieved a 36% ORR (MR, PR) and 58% ... potentially first-in-class, oral anti-cancer agent that modulates Akt and a number of other key ...
... Phase 2 Study of Voreloxin as Single agent Therapy (REVEAL-1 Trial) Interim data from ... E valuation of V or E loxin in A m L ) single agent Phase 2 trial show that voreloxin induces ... Phase 2 portion of this study. Single agent cytarabine is the current treatment standard for ...
... 1 dose escalation trial of voreloxin as a single agent in acute leukemias (N=73) showed that ... The researchers concluded that single agent activity in the relapsed/refractory AML ... voreloxin at a dose of 48 mg/m2 as a single agent once every three weeks. At this dose, ...
... on the battlefield or civilian victims of nerve agent attacks. Valortim(R), in co-development with ... may have efficacy as a therapeutic against nerve agent exposure. -- A study of Valortim(R) in a ... mimics percutaneous exposure. In this model, free agent was measured in both the dermis and blood ...
... of hematological malignancies as both a single agent and in combination with other therapies. This ... with leukemia. Laromustine is a promising agent for that effort." The trial has been designed ... evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de ...
... causing apoptosis in cancer cells. In single agent Phase 1 studies carfilzomib has demonstrated ... currently evaluating carfilzomib as a single agent for the treatment of multiple myeloma in two ... is evaluating carfilzomib as a single agent in a Phase 2 trial of patients with advanced ...
... RCC are warranted either as a single agent or in combination with one of the newer targeted ... antibody, bevacizumab (Avastin). Although each agent can provide some benefit in a subset of patients, ... in multiple tumor types both as a single agent and in combination with other drugs. Agennix ...
... Will Bring Innovative Fluorescent Imaging agent and System Technologies into Clinical ... treatment." The ProSense(R) Activatable Imaging agent platform was developed to provide in vivo ... on the metabolism of the agent to support expanded Phase II clinical trials. ...
... Data from Phase 1 Single agent and Phase 1b Combination Clinical Trials ... Phase 1 trial of voreloxin when used as a single agent in relapsed or refractory patients with ... with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ...
... gadolinium has been shown to have single agent activity in lymphoma and is synergistic with ... Pharmacyclics is developing MGd as an anti-cancer agent with a novel mechanism of action that is designed ... non-overlapping toxicity makes it an appealing agent to use in combination with standard chemotherapy ...
... phase 2 results demonstrating the single agent clinical activity of perifosine in patients ... MA, discussed the phase 2 results on the single agent clinical activity of perifosine in patients with ... summary, the investigators conclude that single agent perifosine showed encouraging activity with ...
... of Clolar(R) (clofarabine) as a single agent in previously untreated, older adult patients ... prognostic factors who received single agent clofarabine exhibited a 45 percent overall ... efficacy findings we are observing with single agent clofarabine, we also see impressive responses in ...
... and preclinical activity of KRX-0401 as a single agent and in combination with novel agents are ... potentially first-in-class, oral anti-cancer agent that modulates Akt and a number of other key ... variety of tumor types. KRX-0401 has shown single agent partial responses in renal cell and ...
... I/II clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with ... of these devastating conditions as both a single agent and in combination with other therapies." Dr. ... evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de ...
... patient enrollment. ALTROPANE molecular imaging agent is an investigational, diagnostic drug developed ... nervous system diagnostic molecular imaging agent -- and a valuable tool to help clinicians make ... and their families. About ALTROPANE Imaging agent and Parkinsonian Syndromes Including Parkinson's ...
... BFPET is FluoroPharma's second cardiovascular PET agent to enter clinical trials. BFPET is a PET blood ... of 70:1, and we look forward to evaluating the agent in human studies." "We are delighted to have ... progress follows on the tail of CardioPET, an agent for the detection of metabolic integrity of the ...
... -Provides Additional Evidence That This Phase II agent Has Good Tolerability and Broad Anti-Microbial ... efficacy could make it a potentially valuable new agent for addressing a variety of ocular infections." ... drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase III ...
... has recently shown very significant single agent activity in a the difficult to treat elderly AML ... (VNP40101M) is an active agent in AML, and we continue to believe that it will ... and second line settings, as either a single agent or in combination with other therapies." The ...
... dacarbazine, and the immunotherapy agent interleukin-2. Dacarbazine as a single agent has minimal activity and interleukin 2 is not ... 10 years. In studies of dacarbazine as a single agent to treat malignant melanoma, median ...
... obtained the rights to develop and market a novel agent for the prevention and treatment of neuropathies ... CXB909, is a small molecule, orally active agent that enhances the effects of nerve growth factor ... "In preclinical studies, our small molecule agent CXB909 has been shown to increase the action of ...
... Regardless of the particular anti-TNF-alpha agent previously used in treatment (adalimumab, ... the efficacy and safety of an anti-TNF-alpha agent in patients previously treated with other ... Reasons for discontinuation of prior anti-TNF agent included lack of efficacy (58 percent), ...
... KRX-0401 Demonstrates Impressive Single agent Efficacy in Patients who Progressed after Failing ... as a secondary endpoint. Best response to single agent perifosine was as follows: Group ... group, best response and median PFS to single agent perifosine was as follows: Group ...
TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
... to commonly used antimetabolite and alkylating agent chemotherapies. The molecule is currently being studied as an oral agent in combination with pemetrexed (Alimta(R)) and as an intravenous agent in combination with temozolomide (Temodar(R)). ...... less toxic and more active than the FDA approved agent ribavirin. Preliminary in vivo toxicology ... "We believe that the addition of a novel agent such as PG301029 to the current standard of care ... based on their transcription targeted therapeutic agent platform. For further information ...
... our belief that ProLindac is an active platinum agent with a favorable side effect profile," stated ... kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to ... ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. Access ...
... benefit for pixantrone when used as single agent therapy in the treatment of multiple relapsed ... prior therapy with doxorubicin, an agent in a similar class with cumulative ... (BBR 2778), a DNA intercalating antitumor agent that contains an aza-anthracenedione molecular ...
Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997
... the company's anticancer vascular-disrupting agent (VDA). The primary objectives of this ... and the dose-limiting toxicities (DLTs) for the agent when administered orally in capsule form every ... intravenously. The oral activity of the agent should markedly improve its clinical and ...... the program. The Altropane molecular imaging agent is being developed by Alseres to aid in the early ... "We believe that Altropane represents an imaging agent that is not only 'first-in-class' in the U.S. ... Altropane Altropane is a molecular imaging agent that specifically binds to the dopamine ...
... mechanism. Angiolix(R) is a promising novel agent for anti-angiogenic cancer therapy. Angiolix has ... kill cancer cells; Alchemix, a chemotherapeutic agent that combines multiple modes of action to ... ("PB"), an HDAC inhibitor and differentiating agent currently a Phase 2 clinical candidate. For ...
... and efficacy of Macroplastique to another bulking agent used in the control group. In the Macroplastique ... available bioabsorbable urethral bulking agent for one year. Of the 247 study ... Macroplastique(R) Implants, an injectable bulking agent for the treatment of adult female stress urinary ...
... Injection, an intravenous sedative-hypnotic agent for monitored anesthesia care (MAC) sedation in ... for use as an intravenous sedative-hypnotic agent for sedation in adult patients undergoing ... LUSEDRA is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) ...
... demonstrated that perifosine is an active, novel agent with the potential to provide clinical benefit to ... Macroglobulinemia (WM) Single agent perifosine achieved a 36% ORR (MR, PR) and 58% ... potentially first-in-class, oral anti-cancer agent that modulates Akt and a number of other key ...
... Phase 2 Study of Voreloxin as Single agent Therapy (REVEAL-1 Trial) Interim data from ... E valuation of V or E loxin in A m L ) single agent Phase 2 trial show that voreloxin induces ... Phase 2 portion of this study. Single agent cytarabine is the current treatment standard for ...
Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
... Receptor Antagonist (TRA), a novel antiplatelet agent that can potentially prevent the formation of ... (golimumab), a once-monthly subcutaneous anti-TNF agent for inflammatory and autoimmune disorders (under ... (asenapine), a novel psychopharmacologic agent (under U.S. review for schizophrenia and acute ...... 1 dose escalation trial of voreloxin as a single agent in acute leukemias (N=73) showed that ... The researchers concluded that single agent activity in the relapsed/refractory AML ... voreloxin at a dose of 48 mg/m2 as a single agent once every three weeks. At this dose, ...
... on the battlefield or civilian victims of nerve agent attacks. Valortim(R), in co-development with ... may have efficacy as a therapeutic against nerve agent exposure. -- A study of Valortim(R) in a ... mimics percutaneous exposure. In this model, free agent was measured in both the dermis and blood ...
Major State Grant Accelerates Research and Development of Novel Cancer Therapy
... developing an over-the-counter skin protective agent with unique antioxidant properties. "SURECAG is ... compound that in combination with an oxidizing agent or agent that generates reactive oxygen species ...... of hematological malignancies as both a single agent and in combination with other therapies. This ... with leukemia. Laromustine is a promising agent for that effort." The trial has been designed ... evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de ...
... causing apoptosis in cancer cells. In single agent Phase 1 studies carfilzomib has demonstrated ... currently evaluating carfilzomib as a single agent for the treatment of multiple myeloma in two ... is evaluating carfilzomib as a single agent in a Phase 2 trial of patients with advanced ...
... RCC are warranted either as a single agent or in combination with one of the newer targeted ... antibody, bevacizumab (Avastin). Although each agent can provide some benefit in a subset of patients, ... in multiple tumor types both as a single agent and in combination with other drugs. Agennix ...
Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
... Champions Biotechnology intends to test the BPU agent utilizing its Biomerk Tumorgraft(TM) Preclinical ... preclinical models. By testing the BPU agent against panels of Biomerk Tumorgrafts from ... M.D., Ph.D. Champions Biotechnology's BPU agent is an antimitotic inhibitor that targets MAPT ...... Will Bring Innovative Fluorescent Imaging agent and System Technologies into Clinical ... treatment." The ProSense(R) Activatable Imaging agent platform was developed to provide in vivo ... on the metabolism of the agent to support expanded Phase II clinical trials. ...
... Data from Phase 1 Single agent and Phase 1b Combination Clinical Trials ... Phase 1 trial of voreloxin when used as a single agent in relapsed or refractory patients with ... with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ...
... gadolinium has been shown to have single agent activity in lymphoma and is synergistic with ... Pharmacyclics is developing MGd as an anti-cancer agent with a novel mechanism of action that is designed ... non-overlapping toxicity makes it an appealing agent to use in combination with standard chemotherapy ...
... phase 2 results demonstrating the single agent clinical activity of perifosine in patients ... MA, discussed the phase 2 results on the single agent clinical activity of perifosine in patients with ... summary, the investigators conclude that single agent perifosine showed encouraging activity with ...
... of Clolar(R) (clofarabine) as a single agent in previously untreated, older adult patients ... prognostic factors who received single agent clofarabine exhibited a 45 percent overall ... efficacy findings we are observing with single agent clofarabine, we also see impressive responses in ...
... and preclinical activity of KRX-0401 as a single agent and in combination with novel agents are ... potentially first-in-class, oral anti-cancer agent that modulates Akt and a number of other key ... variety of tumor types. KRX-0401 has shown single agent partial responses in renal cell and ...
Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
... development of this compound both as a single agent and in combination with other anti-cancer ... Phase 1b/2 clinical trials of XL765 as a single agent and in combination with other targeted agents or ... efficacy in xenograft models, both as a single agent and in combination with other therapies. About ...... I/II clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with ... of these devastating conditions as both a single agent and in combination with other therapies." Dr. ... evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de ...
Poniard Pharmaceuticals Completes Enrollment of Phase 2 Picoplatin Trial in Colorectal Cancer
... is a new generation platinum chemotherapy agent with the potential to become a platform ... this product." Picoplatin is a chemotherapeutic agent that has an improved safety profile compared to ... position picoplatin as the preferred platinum agent for the first-line treatment of ...... patient enrollment. ALTROPANE molecular imaging agent is an investigational, diagnostic drug developed ... nervous system diagnostic molecular imaging agent -- and a valuable tool to help clinicians make ... and their families. About ALTROPANE Imaging agent and Parkinsonian Syndromes Including Parkinson's ...
EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
... substantial, dose-dependent efficacy as a single agent in multiple preclinical models, including tumor ... models. Importantly, ENMD-2076 is an oral agent that has shown an acceptable toxicity profile in ... its significant antitumor potential as a single agent in a variety of tumor types. Through this Phase 1 ...Clinical Update - Debio 0614 (Istaroxime) in Acute Heart Failure
... placebo. "Debio 0614 is a novel intravenous agent combining inotropic and lusitropic properties. ... a trend to decrease heart rate, that makes this agent a promising therapy for the acute heart failure ... Debio 0614 is a first in class luso-inotropic agent with calcium cycling modulating properties. It ...... BFPET is FluoroPharma's second cardiovascular PET agent to enter clinical trials. BFPET is a PET blood ... of 70:1, and we look forward to evaluating the agent in human studies." "We are delighted to have ... progress follows on the tail of CardioPET, an agent for the detection of metabolic integrity of the ...
... -Provides Additional Evidence That This Phase II agent Has Good Tolerability and Broad Anti-Microbial ... efficacy could make it a potentially valuable new agent for addressing a variety of ocular infections." ... drug, the pioneering gene silencing agent bevasiranib, has entered a pivotal Phase III ...
Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
... with the related drug, mitoxantrone, an agent currently approved to treat severe ... [is] a promising immunosuppressant agent suitable for clinical investigation in myasthenia ... Pixantrone Pixantrone is an investigational agent under development for the potential treatment of ...... has recently shown very significant single agent activity in a the difficult to treat elderly AML ... (VNP40101M) is an active agent in AML, and we continue to believe that it will ... and second line settings, as either a single agent or in combination with other therapies." The ...
... dacarbazine, and the immunotherapy agent interleukin-2. Dacarbazine as a single agent has minimal activity and interleukin 2 is not ... 10 years. In studies of dacarbazine as a single agent to treat malignant melanoma, median ...
Other ContentsOther Tags
(Date:5/20/2013)... New Geology articles posted online ... cover a wide swath of geoscience subdisciplines, including ... and paleobotany. Locations studied include Siberia; the Sumatran ... Apuane, Italy; Ukraine; Mars; and the Southeastern U.S. ... Rubies, jadeite, and plate tectonics;, 2. The clear ...
(Date:5/19/2013)... of electricity-producing bacteria that can grow using hydrogen gas ... its sole source of carbon. Researchers at the ... 113th General Meeting of the American Society for Microbiology. ... solely on hydrogen," says Amit Kumar, a researcher on ... of the Lovley Lab Group at the university. , ...
(Date:5/18/2013)... Research Foundation is honored to announce the first AGA-Caroline ... which will support Andrew D. Rhim, MD, from the ... Philadelphia, as he furthers his research on the role ... , "The AGA Research Foundation is humbled to issue ... AGA Legacy Society members," said Nicholas F. LaRusso, MD, ...
Breaking Biology News(10 mins):New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 2New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 3New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 4New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 5New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 6New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 7New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 8New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 9New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 10New in GEOLOGY: Gems, Darwin, Mars, Hemp, Snowball Earth, a Siberian Impact Crater, and More 11AGA Research Foundation grant furthers digestive cancer research 2(Date:5/22/2013)... Margate City, NJ (PRWEB) May 22, 2013 ... from solved. In some states, up to twenty-seven percent ... half of all bankruptcies of private citizens in the U.S. ... medical care also affects prescription drugs, meaning that many patients ... doctor, or even get them filled at all. That's ...
(Date:5/22/2013)... Beginning Aug. 22, teens are invited ... Spirit of Innovation Challenge . The annual program ... and open to students ages 13 - 18 from ... Challenge celebrates the life and entrepreneurial spirit of astronaut ... The program challenges teens to work in teams of ...
(Date:5/22/2013)... May 22, 2013 The 2013 release of ... is the largest change to hit the field of mental ... is will help prepare for the release with a Webinar ... been trained knowing no other diagnostic scheme besides the now ... manual will be released worldwide. In honor of this event, ...
(Date:5/22/2013)... May 22, 2013 Abadir Associates, a ... treatments for optimal results, is offering a new technique ... neck. The practice has successfully treated multiple patients ... “Basically, this approach is for women who want to ... dermatologist Dr. Michelle Abadir of Abadir Associates. ...
(Date:5/22/2013)... May 22 2013 - Research presented today shows ... in rats similar to those produced by drugs ... presented by addiction expert Francesco Leri, Associate Professor ... University of Guelph, suggest food addiction could explain, ... These results were presented at the 2013 ...
Breaking Medicine News(10 mins):Health News:Lyrica Discount Cards Now Available From MedicationDiscountCard.com 2Health News:Conrad Foundation Announces 2013-2014 Spirit of Innovation Challenge Launch Date 2Health News:What You Need to Know About DSM-5: The Asheville Jung Center is Hosting a Webinar Tonight on the New Material in DSM-5 2Health News:Westchester Dermatologist Abadir Associates Offers New Neck Lift Surgery Alternative 2Health News:Addiction to unhealthy foods could help explain the global obesity epidemic 2[0] Lyrica Discount Cards Now Available From MedicationDiscountCard.com[0] Conrad Foundation Announces 2013-2014 Spirit of Innovation Challenge Launch Date[0] What You Need to Know About DSM-5: The Asheville Jung Center is Hosting a Webinar Tonight on the New Material in DSM-5[0] Westchester Dermatologist Abadir Associates Offers New Neck Lift Surgery Alternative[0] Addiction to unhealthy foods could help explain the global obesity epidemic
InbreedingIncisorIndehiscentInducerInferiorInflorescenceInformaticsInfundibulumInitiationInsertInitiatorInsectaInsectivoresInsertion
Other Tags| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |